TY - JOUR AU - Busse, R. AU - Blumel, M. PY - 2014 DA - 2014// TI - Germany: health system review JO - Health systems Transit VL - 16 ID - Busse2014 ER - TY - JOUR AU - Bouslouk, M. PY - 2016 DA - 2016// TI - G-BA benefit assessment of new orphan drugs in Germany: the first five years JO - Expert Opin Orphan Drugs VL - 4 UR - https://doi.org/10.1517/21678707.2016.1166950 DO - 10.1517/21678707.2016.1166950 ID - Bouslouk2016 ER - TY - STD TI - IQWiG. General Methods. Version 5.0 of 10 July 2017. 2017. https://www.iqwig.de/download/General-Methods_Version-5-0.pdf UR - https://www.iqwig.de/download/General-Methods_Version-5-0.pdf ID - ref3 ER - TY - JOUR AU - Skipka, G. AU - Wieseler, B. AU - Kaiser, T. AU - Thomas, S. AU - Bender, R. AU - Windeler, J. PY - 2016 DA - 2016// TI - Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs JO - Biom J Biometrische Zeitschrift VL - 58 UR - https://doi.org/10.1002/bimj.201300274 DO - 10.1002/bimj.201300274 ID - Skipka2016 ER - TY - STD TI - IQWiG. Validity of surrogate endpoints in oncology. Version 1.1. Cologne: IQWiG. 2011. https://www.iqwig.de/download/A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf UR - https://www.iqwig.de/download/A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf ID - ref5 ER - TY - STD TI - FJC. Supplement to the FJC rules of procedure. Chapter 5. [German]. 2011. https://www.g-ba.de/richtlinien/anlage/167/ UR - https://www.g-ba.de/richtlinien/anlage/167/ ID - ref6 ER - TY - JOUR AU - Lebioda, A. AU - Gasche, D. AU - Dippel, F. W. AU - Theobald, K. AU - Plantör, S. PY - 2014 DA - 2014// TI - Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland JO - Health Econ Rev VL - 4 UR - https://doi.org/10.1186/s13561-014-0031-5 DO - 10.1186/s13561-014-0031-5 ID - Lebioda2014 ER - TY - JOUR AU - Ruof, J. AU - Schwartz, F. W. AU - Schulenburg, J. M. AU - Dintsios, C. M. PY - 2014 DA - 2014// TI - Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation JO - Eur J Health Econ VL - 15 UR - https://doi.org/10.1007/s10198-013-0495-y DO - 10.1007/s10198-013-0495-y ID - Ruof2014 ER - TY - JOUR AU - Staab, T. R. AU - Isbary, G. AU - Walter, M. AU - Mariotti Nesurini, S. AU - Dintsios, C. M. AU - Schulenburg JM, G. AU - Amelung, V. E. AU - Ruof, J. PY - 2018 DA - 2018// TI - “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health JO - Econ Rev VL - 8 ID - Staab2018 ER - TY - STD TI - GKV-SV. Framework agreement between the National Association of SHI Funds and Pharmaceutical Companies Associations [in German]. 2016. https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf Accessed 1 Aug 2018. UR - https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf ID - ref10 ER - TY - JOUR AU - Ludwig, S. AU - Dintsios, C. M. PY - 2016 DA - 2016// TI - Arbitration board setting reimbursement amounts for pharmaceutical innovations in Germany when Price negations between payers and manufacturers fail: an empirical analysis of 5 Years’ experience JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.05.016 DO - 10.1016/j.jval.2016.05.016 ID - Ludwig2016 ER - TY - JOUR AU - Horn, H. AU - Nink, K. AU - McGauran, N. AU - Wieseler, B. PY - 2014 DA - 2014// TI - Early benefit assessment of new drugs in Germany - results from 2011 to 2012 JO - Health Policy VL - 116 UR - https://doi.org/10.1016/j.healthpol.2013.12.008 DO - 10.1016/j.healthpol.2013.12.008 ID - Horn2014 ER - TY - JOUR AU - Fischer, K. E. AU - Stargardt, T. PY - 2014 DA - 2014// TI - Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee's decisions JO - Med Dec Mak VL - 34 UR - https://doi.org/10.1177/0272989X14546377 DO - 10.1177/0272989X14546377 ID - Fischer2014 ER - TY - JOUR AU - Bless, H. H. AU - Seidlitz, C. AU - Ohlmeier, C. AU - Millas, C. PY - 2018 DA - 2018// TI - Involvement of scientific societies in early benefit assessment: Simulated participation or valuable additional input? JO - Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen VL - 130 UR - https://doi.org/10.1016/j.zefq.2017.09.012 DO - 10.1016/j.zefq.2017.09.012 ID - Bless2018 ER - TY - BOOK PY - 2016 DA - 2016// TI - Verbesserung der Patientenversorgung durch Innovation und Qualität ID - ref15 ER - TY - CHAP AU - Cassel, D. i. e. t. e. r. AU - Ulrich, V. o. l. k. e. r. PY - 2015 DA - 2015// TI - Literaturverzeichnis BT - AMNOG auf dem ökonomischen Prüfstand UR - https://doi.org/10.5771/9783845271521-171 DO - 10.5771/9783845271521-171 ID - Cassel2015 ER - TY - JOUR AU - Rasch, A. AU - Dintsios, C. M. PY - 2015 DA - 2015// TI - Subgroups in the early benefit assessment of pharmaceuticals: a methodical review JO - Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen VL - 109 UR - https://doi.org/10.1016/j.zefq.2015.01.001 DO - 10.1016/j.zefq.2015.01.001 ID - Rasch2015 ER - TY - JOUR AU - Ruof, J. AU - Dintsios, C. -. M. AU - Schwartz, F. W. PY - 2014 DA - 2014// TI - Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.05.001 DO - 10.1016/j.jval.2014.05.001 ID - Ruof2014 ER - TY - JOUR AU - Herpers, M. a. t. t. h. i. a. s. AU - Dintsios, C. h. a. r. a. l. a. b. o. s. -. M. a. r. k. o. s. PY - 2018 DA - 2018// TI - Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany JO - The European Journal of Health Economics VL - 20 UR - https://doi.org/10.1007/s10198-018-0981-3 DO - 10.1007/s10198-018-0981-3 ID - Herpers2018 ER - TY - JOUR AU - Cohen, J. PY - 1960 DA - 1960// TI - A coefficient of agreement for nominal scales JO - Educ Psychol Meas VL - 20 UR - https://doi.org/10.1177/001316446002000104 DO - 10.1177/001316446002000104 ID - Cohen1960 ER - TY - JOUR AU - Fleiss, J. L. PY - 1971 DA - 1971// TI - Measuring nominal scale agreement among many raters JO - Psychol Bull VL - 76 UR - https://doi.org/10.1037/h0031619 DO - 10.1037/h0031619 ID - Fleiss1971 ER - TY - BOOK AU - Altmann, D. PY - 1991 DA - 1991// TI - Practical statistics for medical research PB - Hall CY - London ID - Altmann1991 ER - TY - JOUR AU - Landis, J. R. AU - Koch, G. G. PY - 1977 DA - 1977// TI - The measurement of observer agreement for categorical data JO - Biometrics. VL - 33 UR - https://doi.org/10.2307/2529310 DO - 10.2307/2529310 ID - Landis1977 ER - TY - STD TI - IQWiG. Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Addendum to Commission A16–15. 2016. https://www.iqwig.de/download/A16-15_Ticagrelor_Extract-of-dossier-assessment.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A16-15_Ticagrelor_Extract-of-dossier-assessment.pdf ID - ref24 ER - TY - STD TI - IQWiG. Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V. 2016. https://www.iqwig.de/download/A16-15_Ticagrelor_Extract-of-dossier-assessment.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A16-15_Ticagrelor_Extract-of-dossier-assessment.pdf ID - ref25 ER - TY - STD TI - FJC. Resolution on Ticagrelor [German]. 2016. https://www.g-ba.de/downloads/39-261-2703/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220_BAnz.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/39-261-2703/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220_BAnz.pdf ID - ref26 ER - TY - STD TI - FJC. Decision Rationale Ticagrelor [German]. 2016. https://www.g-ba.de/downloads/40-268-3975/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220_TrG.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/40-268-3975/2016-09-15_AM-RL-XII_Ticagrelor_nAWG_D-220_TrG.pdf ID - ref27 ER - TY - STD TI - IQWiG. Belatacept (Addendum to Commission A15–25). 2015. https://www.iqwig.de/download/A15-51_Belatacept_Addendum-to-Commission-A15-25.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A15-51_Belatacept_Addendum-to-Commission-A15-25.pdf ID - ref28 ER - TY - STD TI - IQWiG. Belatacept – Benefit assessment according to §35a Social Code Book V. 2015. https://www.iqwig.de/download/A15-25_Belatacept_Exctract-of-dossier-assessment.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A15-25_Belatacept_Exctract-of-dossier-assessment.pdf ID - ref29 ER - TY - STD TI - FJC. Resolution on Belatacept [German]. 2016. https://www.g-ba.de/downloads/91-1385-178/2016-04-21_Geltende-Fassung_Belatacept_D-173.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/91-1385-178/2016-04-21_Geltende-Fassung_Belatacept_D-173.pdf ID - ref30 ER - TY - STD TI - FJC. Decision rationale Belatacept [German]. 2016. https://www.g-ba.de/downloads/40-268-3526/2016-01-07_AM-RL-XII_Belatacept_2015-07-15-D-173_TrG.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/40-268-3526/2016-01-07_AM-RL-XII_Belatacept_2015-07-15-D-173_TrG.pdf ID - ref31 ER - TY - STD TI - IQWiG. Ixekizumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V. 2017. https://www.iqwig.de/download/A17-07_Ixekizumab_Extract-of-dossier-assessment_V1-0.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A17-07_Ixekizumab_Extract-of-dossier-assessment_V1-0.pdf ID - ref32 ER - TY - STD TI - IQWiG. Ixekizumab (plaque psoriasis) – Addendum to Commission A17–07. 2017. https://www.iqwig.de/download/A17-30_Ixekizumab_Addendum-to-Commission-A17-07_V1-0.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A17-30_Ixekizumab_Addendum-to-Commission-A17-07_V1-0.pdf ID - ref33 ER - TY - STD TI - FJC. Resolution on Ixekizumab [German]. 2017. https://www.g-ba.de/downloads/39-261-3036/2017-08-17_AM-RL-XII_Ixekizumab_D-275_BAnz.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/39-261-3036/2017-08-17_AM-RL-XII_Ixekizumab_D-275_BAnz.pdf ID - ref34 ER - TY - STD TI - FJC. Decision rationale Ixekizumab [German]. 2017. https://www.g-ba.de/downloads/40-268-4526/2017-08-17_AM-RL-XII_Ixekizumab_D-275_TrG.pdf. Accessed 1 Aug 2018. UR - https://www.g-ba.de/downloads/40-268-4526/2017-08-17_AM-RL-XII_Ixekizumab_D-275_TrG.pdf ID - ref35 ER - TY - STD TI - IQWiG. Aflibercept (Addendum to Commission A14–32). 2015. https://www.iqwig.de/download/A15-05_Addendum-to-Commission-A14-32_Aflibercept.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A15-05_Addendum-to-Commission-A14-32_Aflibercept.pdf ID - ref36 ER - TY - STD TI - IQWiG. Opicapone (Parkinson disease) – Addendum to Commission A16–61. 2017. https://www.iqwig.de/download/A17-04_Opicapone_Addendum-to-Commission-A16-61_V1-0.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A17-04_Opicapone_Addendum-to-Commission-A16-61_V1-0.pdf ID - ref37 ER - TY - STD TI - IQWiG. Ceritinib (non-small cell lung cancer) – Addendum to Commission A16–62. 2017. https://www.iqwig.de/download/A17-05_Ceritinib_Addendum-to-Commission-A16-62_V1-1.pdf. Accessed 1 Aug 2018. UR - https://www.iqwig.de/download/A17-05_Ceritinib_Addendum-to-Commission-A16-62_V1-1.pdf ID - ref38 ER - TY - STD TI - Röhmel J. Gutachten zum Vorschlag des IQWiG zur Bewertung des Ausmaßes des Zusatznutzens im Rahmen der Nutzenbewertung von Arzneimitteln nach §35a SGB V. 2012. ID - ref39 ER - TY - JOUR AU - Witte, J. AU - Greiner, W. PY - 2013 DA - 2013// TI - Problembefunde der Quantifizierung des Zusatznutzens im Rahmen der frühen Arzneimittelnutzenbewertung JO - Gesundh ökon Qual manag VL - 18 UR - https://doi.org/10.1055/s-0033-1350539 DO - 10.1055/s-0033-1350539 ID - Witte2013 ER - TY - JOUR AU - Vach, W. PY - 2014 DA - 2014// TI - Quantifying the additional clinical benefit of new medicines: little - considerable - significant - 6 remarks from a biometrician’s point of view JO - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) VL - 76 UR - https://doi.org/10.1055/s-0033-1363682 DO - 10.1055/s-0033-1363682 ID - Vach2014 ER - TY - JOUR AU - Fischer, K. E. AU - Heisser, T. AU - Stargardt, T. PY - 2016 DA - 2016// TI - Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia JO - Health Policy VL - 120 UR - https://doi.org/10.1016/j.healthpol.2016.08.001 DO - 10.1016/j.healthpol.2016.08.001 ID - Fischer2016 ER - TY - JOUR AU - Niehaus, I. n. e. s. AU - Dintsios, C. h. a. r. a. l. a. b. o. s. -. M. a. r. k. o. s. PY - 2018 DA - 2018// TI - Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs JO - Health Policy VL - 122 UR - https://doi.org/10.1016/j.healthpol.2018.03.017 DO - 10.1016/j.healthpol.2018.03.017 ID - Niehaus2018 ER - TY - JOUR AU - Maclure, M. AU - Willett, W. C. PY - 1987 DA - 1987// TI - Misinterpretation And Misuse Of The Kappa Statistic JO - Am J Epidemiol VL - 126 UR - https://doi.org/10.1093/aje/126.2.161 DO - 10.1093/aje/126.2.161 ID - Maclure1987 ER - TY - JOUR AU - Thompson, W. D. AU - Walter, S. D. PY - 1988 DA - 1988// TI - Response kappa and the concept of independent errors JO - J Clin Epidemiol VL - 41 UR - https://doi.org/10.1016/0895-4356(88)90033-9 DO - 10.1016/0895-4356(88)90033-9 ID - Thompson1988 ER - TY - JOUR AU - Uebersax, J. S. PY - 1987 DA - 1987// TI - Diversity of decision-making models and the measurement of interrater agreement JO - Psychol Bull VL - 101 UR - https://doi.org/10.1037/0033-2909.101.1.140 DO - 10.1037/0033-2909.101.1.140 ID - Uebersax1987 ER - TY - JOUR AU - Grouven, U. AU - Bender, R. AU - Ziegler, A. AU - Lange, S. PY - 2007 DA - 2007// TI - Der Kappa-Koeffizient JO - Dtsch med Wochenschr VL - 132 UR - https://doi.org/10.1055/s-2007-959046 DO - 10.1055/s-2007-959046 ID - Grouven2007 ER - TY - JOUR AU - Glaeske, G. PY - 2016 DA - 2016// TI - Drug assessment: IQWiG, G-BA, and an international comparison JO - Internist VL - 57 UR - https://doi.org/10.1007/s00108-015-3830-9 DO - 10.1007/s00108-015-3830-9 ID - Glaeske2016 ER - TY - STD TI - Shah K, Devlin N. Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity. OHE. 2012. doi: 10.2139/ssrn.2633405 ID - ref49 ER - TY - JOUR AU - Maison, P. AU - Zanetti, L. AU - Solesse, A. AU - Bouvenot, G. AU - Massol, J. PY - 2013 DA - 2013// TI - The public health benefit of medicines: how it has been assessed in France? The principles and results of five years’ experience JO - Health Policy VL - 112 UR - https://doi.org/10.1016/j.healthpol.2013.04.007 DO - 10.1016/j.healthpol.2013.04.007 ID - Maison2013 ER - TY - JOUR AU - Schmitz, S. AU - McCullagh, L. AU - Adams, R. AU - Barry, M. AU - Walsh, C. PY - 2016 DA - 2016// TI - Identifying and revealing the importance of decision-making criteria for health technology assessment: a retrospective analysis of reimbursement recommendations in Ireland JO - PharmacoEcon. VL - 34 UR - https://doi.org/10.1007/s40273-016-0406-z DO - 10.1007/s40273-016-0406-z ID - Schmitz2016 ER - TY - JOUR AU - Kleijnen, S. AU - George, E. AU - Goulden, S. AU - d'Andon, A. AU - Vitre, P. AU - Osinska, B. PY - 2012 DA - 2012// TI - Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions JO - Value Health VL - 15 UR - https://doi.org/10.1016/j.jval.2012.04.010 DO - 10.1016/j.jval.2012.04.010 ID - Kleijnen2012 ER -